Annual EBIT
-$21.24 M
-$393.70 K-1.89%
April 30, 2024
Summary
- As of February 8, 2025, IPA annual earnings before interest & taxes is -$21.24 million, with the most recent change of -$393.70 thousand (-1.89%) on April 30, 2024.
- During the last 3 years, IPA annual EBIT has fallen by -$17.32 million (-441.61%).
- IPA annual EBIT is now -31520.56% below its all-time high of $67.60 thousand, reached on December 31, 2013.
Performance
IPA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.15 M
+$1.33 M+38.23%
October 31, 2024
Summary
- As of February 8, 2025, IPA quarterly earnings before interest & taxes is -$2.15 million, with the most recent change of +$1.33 million (+38.23%) on October 31, 2024.
- Over the past year, IPA quarterly EBIT has increased by +$1.33 million (+38.23%).
- IPA quarterly EBIT is now -1963.64% below its all-time high of $115.50 thousand, reached on December 1, 2013.
Performance
IPA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$22.06 M
-$248.80 K-1.14%
October 31, 2024
Summary
- As of February 8, 2025, IPA TTM earnings before interest & taxes is -$22.06 million, with the most recent change of -$248.80 thousand (-1.14%) on October 31, 2024.
- Over the past year, IPA TTM EBIT has dropped by -$248.80 thousand (-1.14%).
- IPA TTM EBIT is now -29121.71% below its all-time high of $76.00 thousand, reached on June 30, 2014.
Performance
IPA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
IPA EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.9% | +38.2% | -1.1% |
| 3 y3 years | -441.6% | +38.2% | -1.1% |
| 5 y5 years | -344.7% | +38.2% | -1.1% |
IPA EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -441.6% | at low | -13.1% | +84.5% | -90.0% | at low |
| 5 y | 5-year | -635.4% | at low | -2199.7% | +84.5% | -1543.2% | at low |
| alltime | all time | <-9999.0% | at low | -1963.6% | +84.5% | <-9999.0% | at low |
ImmunoPrecise Antibodies EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$2.15 M(-38.2%) | -$22.06 M(+1.1%) |
| Jul 2024 | - | -$3.48 M(-74.9%) | -$21.81 M(+3.1%) |
| Apr 2024 | -$21.24 M(+1.9%) | -$13.86 M(+442.5%) | -$21.14 M(+82.2%) |
| Jan 2024 | - | -$2.56 M(+34.2%) | -$11.61 M(-6.8%) |
| Oct 2023 | - | -$1.90 M(-32.5%) | -$12.46 M(-23.0%) |
| Jul 2023 | - | -$2.82 M(-34.8%) | -$16.17 M(-22.8%) |
| Apr 2023 | -$20.85 M(+65.9%) | -$4.33 M(+27.0%) | -$20.94 M(+4.5%) |
| Jan 2023 | - | -$3.41 M(-39.3%) | -$20.05 M(+2.9%) |
| Oct 2022 | - | -$5.62 M(-26.0%) | -$19.48 M(+10.2%) |
| Jul 2022 | - | -$7.59 M(+121.3%) | -$17.68 M(+41.7%) |
| Apr 2022 | -$12.56 M(+220.3%) | -$3.43 M(+20.9%) | -$12.48 M(+3.2%) |
| Jan 2022 | - | -$2.84 M(-25.6%) | -$12.09 M(+20.2%) |
| Oct 2021 | - | -$3.82 M(+59.5%) | -$10.06 M(+58.0%) |
| Jul 2021 | - | -$2.39 M(-21.4%) | -$6.36 M(+56.5%) |
| Apr 2021 | -$3.92 M(+35.8%) | -$3.04 M(+278.1%) | -$4.07 M(+106.8%) |
| Jan 2021 | - | -$804.90 K(+545.0%) | -$1.97 M(+46.5%) |
| Oct 2020 | - | -$124.80 K(+33.3%) | -$1.34 M(-31.4%) |
| Jul 2020 | - | -$93.60 K(-90.1%) | -$1.96 M(-32.0%) |
| Apr 2020 | -$2.89 M(-39.5%) | -$943.50 K(+423.0%) | -$2.87 M(-39.5%) |
| Jan 2020 | - | -$180.40 K(-75.6%) | -$4.75 M(-8.8%) |
| Oct 2019 | - | -$738.30 K(-27.1%) | -$5.21 M(-0.2%) |
| Jul 2019 | - | -$1.01 M(-64.1%) | -$5.22 M(+9.9%) |
| Apr 2019 | -$4.78 M(+26.8%) | -$2.82 M(+341.3%) | -$4.75 M(+37.3%) |
| Jan 2019 | - | -$639.20 K(-14.7%) | -$3.46 M(-7.2%) |
| Oct 2018 | - | -$749.20 K(+37.9%) | -$3.73 M(+1.8%) |
| Jul 2018 | - | -$543.40 K(-64.5%) | -$3.66 M(-2.7%) |
| Apr 2018 | -$3.77 M(-9.0%) | -$1.53 M(+68.2%) | -$3.77 M(+16.8%) |
| Jan 2018 | - | -$908.80 K(+33.0%) | -$3.23 M(-42.8%) |
| Oct 2017 | - | -$683.20 K(+5.6%) | -$5.64 M(+13.5%) |
| Jul 2017 | - | -$646.70 K(-34.4%) | -$4.97 M(+14.8%) |
| Apr 2017 | -$4.14 M(>+9900.0%) | -$986.50 K(-70.3%) | -$4.33 M(+29.5%) |
| Jan 2017 | - | -$3.32 M(>+9900.0%) | -$3.34 M(+6516.0%) |
| Sep 2016 | - | -$10.50 K(+45.8%) | -$50.50 K(+19.7%) |
| Jun 2016 | - | -$7200.00(+132.3%) | -$42.20 K(+49.1%) |
| Mar 2016 | - | -$3100.00(-89.6%) | -$28.30 K(+23.0%) |
| Dec 2015 | -$24.80 K(-55.8%) | - | - |
| Dec 2015 | - | -$29.70 K(+1250.0%) | -$23.00 K(+505.3%) |
| Sep 2015 | - | -$2200.00(-132.8%) | -$3800.00(-86.7%) |
| Jun 2015 | - | $6700.00(+204.5%) | -$28.50 K(-22.8%) |
| Mar 2015 | - | $2200.00(-121.0%) | -$36.90 K(-34.3%) |
| Dec 2014 | -$56.10 K(-183.0%) | - | - |
| Dec 2014 | - | -$10.50 K(-61.0%) | -$56.20 K(-180.5%) |
| Sep 2014 | - | -$26.90 K(+1482.4%) | $69.80 K(-8.2%) |
| Jun 2014 | - | -$1700.00(-90.1%) | $76.00 K(+16.0%) |
| Mar 2014 | - | -$17.10 K(-114.8%) | $65.50 K(+0.8%) |
| Dec 2013 | $67.60 K(-170.7%) | - | - |
| Dec 2013 | - | $115.50 K(-658.0%) | $65.00 K(-165.1%) |
| Sep 2013 | - | -$20.70 K(+69.7%) | -$99.90 K(+2.4%) |
| Jun 2013 | - | -$12.20 K(-30.7%) | -$97.60 K(+6.3%) |
| Mar 2013 | - | -$17.60 K(-64.4%) | -$91.80 K(-4.4%) |
| Dec 2012 | -$95.60 K(-65.7%) | - | - |
| Dec 2012 | - | -$49.40 K(+168.5%) | -$96.00 K(-39.0%) |
| Sep 2012 | - | -$18.40 K(+187.5%) | -$157.50 K(-22.7%) |
| Jun 2012 | - | -$6400.00(-70.6%) | -$203.70 K(-21.7%) |
| Mar 2012 | - | -$21.80 K(-80.3%) | -$260.20 K(+8.9%) |
| Dec 2011 | -$278.50 K(-94.6%) | - | - |
| Dec 2011 | - | -$110.90 K(+71.7%) | -$238.90 K(-95.4%) |
| Sep 2011 | - | -$64.60 K(+2.7%) | -$5.19 M(+0.3%) |
| Jun 2011 | - | -$62.90 K(>+9900.0%) | -$5.17 M(+1.2%) |
| Mar 2011 | - | -$500.00(-100.0%) | -$5.11 M(-1.1%) |
| Dec 2010 | -$5.13 M(+328.7%) | - | - |
| Dec 2010 | - | -$5.06 M(>+9900.0%) | -$5.17 M(+317.3%) |
| Sep 2010 | - | -$48.70 K(+6857.1%) | -$1.24 M(-0.1%) |
| Jun 2010 | - | -$700.00(-98.8%) | -$1.24 M(-3.0%) |
| Mar 2010 | - | -$59.90 K | -$1.28 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | -$1.20 M(+168.8%) | - | - |
| Dec 2009 | - | -$1.13 M(+2186.6%) | -$1.27 M(+157.4%) |
| Sep 2009 | - | -$49.40 K(+25.1%) | -$493.80 K(+31.3%) |
| Jun 2009 | - | -$39.50 K(-24.5%) | -$376.20 K(-7.6%) |
| Mar 2009 | - | -$52.30 K(-85.2%) | -$407.30 K(-2.3%) |
| Dec 2008 | -$445.10 K(-22.7%) | - | - |
| Dec 2008 | - | -$352.60 K(-617.0%) | -$416.80 K(-24.4%) |
| Sep 2008 | - | $68.20 K(-196.6%) | -$551.50 K(-14.1%) |
| Jun 2008 | - | -$70.60 K(+14.2%) | -$642.20 K(+2.3%) |
| Mar 2008 | - | -$61.80 K(-87.3%) | -$627.70 K(+2.1%) |
| Dec 2007 | -$575.80 K(+175.2%) | - | - |
| Dec 2007 | - | -$487.30 K(+2065.8%) | -$614.70 K(+1539.2%) |
| Sep 2007 | - | -$22.50 K(-59.9%) | -$37.50 K(-24.7%) |
| Jun 2007 | - | -$56.10 K(+15.0%) | -$49.80 K(-75.7%) |
| Mar 2007 | - | -$48.80 K(-154.3%) | -$205.20 K(-0.9%) |
| Dec 2006 | -$209.20 K(+23.3%) | - | - |
| Dec 2006 | - | $89.90 K(-358.3%) | -$207.10 K(-41.6%) |
| Sep 2006 | - | -$34.80 K(-83.5%) | -$354.80 K(+5.7%) |
| Jun 2006 | - | -$211.50 K(+317.2%) | -$335.80 K(+109.0%) |
| Mar 2006 | - | -$50.70 K(-12.3%) | -$160.70 K(-42.1%) |
| Dec 2005 | -$169.70 K(+10.1%) | - | - |
| Dec 2005 | - | -$57.80 K(+265.8%) | -$277.70 K(-29.9%) |
| Sep 2005 | - | -$15.80 K(-56.6%) | -$396.10 K(+6.1%) |
| Jun 2005 | - | -$36.40 K(-78.3%) | -$373.20 K(+1.9%) |
| Mar 2005 | - | -$167.70 K(-4.8%) | -$366.10 K(+51.6%) |
| Dec 2004 | -$154.10 K(-30.2%) | - | - |
| Dec 2004 | - | -$176.20 K(-2581.7%) | -$241.50 K(+14.1%) |
| Sep 2004 | - | $7100.00(-124.2%) | -$211.60 K(-11.7%) |
| Jun 2004 | - | -$29.30 K(-32.0%) | -$239.60 K(-2.2%) |
| Mar 2004 | - | -$43.10 K(-70.5%) | -$245.00 K(+7.6%) |
| Dec 2003 | -$220.80 K(+119.7%) | - | - |
| Dec 2003 | - | -$146.30 K(+600.0%) | -$227.60 K(+122.3%) |
| Sep 2003 | - | -$20.90 K(-39.8%) | -$102.40 K(+0.3%) |
| Jun 2003 | - | -$34.70 K(+35.0%) | -$102.10 K(+0.6%) |
| Mar 2003 | - | -$25.70 K(+21.8%) | -$101.50 K(+0.9%) |
| Dec 2002 | -$100.50 K(-19.8%) | - | - |
| Dec 2002 | - | -$21.10 K(+2.4%) | -$100.60 K(+28.0%) |
| Sep 2002 | - | -$20.60 K(-39.6%) | -$78.60 K(-29.8%) |
| Jun 2002 | - | -$34.10 K(+37.5%) | -$112.00 K(-25.5%) |
| Mar 2002 | - | -$24.80 K(-2855.6%) | -$150.40 K(-0.7%) |
| Dec 2001 | -$125.30 K(+25.2%) | - | - |
| Dec 2001 | - | $900.00(-101.7%) | -$151.40 K(-15.7%) |
| Sep 2001 | - | -$54.00 K(-25.5%) | -$179.70 K(+21.3%) |
| Jun 2001 | - | -$72.50 K(+181.0%) | -$148.10 K(+46.1%) |
| Mar 2001 | - | -$25.80 K(-5.8%) | -$101.40 K(+1.5%) |
| Dec 2000 | -$100.10 K(-15.7%) | - | - |
| Dec 2000 | - | -$27.40 K(+22.3%) | -$99.90 K(+7.2%) |
| Sep 2000 | - | -$22.40 K(-13.2%) | -$93.20 K(-3.7%) |
| Jun 2000 | - | -$25.80 K(+6.2%) | -$96.80 K(-9.9%) |
| Mar 2000 | - | -$24.30 K(+17.4%) | -$107.40 K(-9.4%) |
| Dec 1999 | -$118.70 K(-1.8%) | - | - |
| Dec 1999 | - | -$20.70 K(-20.4%) | -$118.50 K(+7.6%) |
| Sep 1999 | - | -$26.00 K(-28.6%) | -$110.10 K(-5.2%) |
| Jun 1999 | - | -$36.40 K(+2.8%) | -$116.10 K(-5.5%) |
| Mar 1999 | - | -$35.40 K(+187.8%) | -$122.90 K(+0.8%) |
| Dec 1998 | -$120.90 K(-40.0%) | - | - |
| Dec 1998 | - | -$12.30 K(-61.6%) | -$121.90 K(-24.1%) |
| Sep 1998 | - | -$32.00 K(-25.9%) | -$160.70 K(-3.0%) |
| Jun 1998 | - | -$43.20 K(+25.6%) | -$165.70 K(-18.0%) |
| Mar 1998 | - | -$34.40 K(-32.7%) | -$202.00 K(+0.5%) |
| Dec 1997 | -$201.40 K(+23.9%) | - | - |
| Dec 1997 | - | -$51.10 K(+38.1%) | -$201.00 K(+34.1%) |
| Sep 1997 | - | -$37.00 K(-53.5%) | -$149.90 K(+32.8%) |
| Jun 1997 | - | -$79.50 K(+138.0%) | -$112.90 K(+238.0%) |
| Mar 1997 | - | -$33.40 K | -$33.40 K |
| Dec 1996 | -$162.50 K | - | - |
FAQ
- What is ImmunoPrecise Antibodies annual earnings before interest & taxes?
- What is the all time high annual EBIT for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies annual EBIT year-on-year change?
- What is ImmunoPrecise Antibodies quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies quarterly EBIT year-on-year change?
- What is ImmunoPrecise Antibodies TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies TTM EBIT year-on-year change?
What is ImmunoPrecise Antibodies annual earnings before interest & taxes?
The current annual EBIT of IPA is -$21.24 M
What is the all time high annual EBIT for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high annual earnings before interest & taxes is $67.60 K
What is ImmunoPrecise Antibodies annual EBIT year-on-year change?
Over the past year, IPA annual earnings before interest & taxes has changed by -$393.70 K (-1.89%)
What is ImmunoPrecise Antibodies quarterly earnings before interest & taxes?
The current quarterly EBIT of IPA is -$2.15 M
What is the all time high quarterly EBIT for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high quarterly earnings before interest & taxes is $115.50 K
What is ImmunoPrecise Antibodies quarterly EBIT year-on-year change?
Over the past year, IPA quarterly earnings before interest & taxes has changed by +$1.33 M (+38.23%)
What is ImmunoPrecise Antibodies TTM earnings before interest & taxes?
The current TTM EBIT of IPA is -$22.06 M
What is the all time high TTM EBIT for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high TTM earnings before interest & taxes is $76.00 K
What is ImmunoPrecise Antibodies TTM EBIT year-on-year change?
Over the past year, IPA TTM earnings before interest & taxes has changed by -$248.80 K (-1.14%)